Paper35968356
Breast cancer: molecular mechanisms of underlying resistance and therapeutic approaches.
Tufail M and 2 others. Am J Cancer Res, 2022. Cited by 69 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Breast cancer: molecular mechanisms of underlying resistance and therapeutic approaches. Papers, record 35968356. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35968356
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References262
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 17957337 | Molecular basis of invasion in breast cancer. | Cell Mol Life Sci | 2007 | https://conductscience.org/library/papers/17957337 | PubMed |
| 2 | 26122181 | ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. | Nat Rev Clin Oncol | 2015 | https://conductscience.org/library/papers/26122181 | PubMed |
| 3 | 7564505 | Topoisomerase II alpha gene expression in childhood acute lymphoblastic leukemia. | Leukemia | 1995 | https://conductscience.org/library/papers/7564505 | PubMed |
| 4 | 30867218 | Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer. | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/30867218 | PubMed |
| 5 | 31548545 | Breast cancer. | Nat Rev Dis Primers | 2019 | https://conductscience.org/library/papers/31548545 | PubMed |
| 6 | 2319611 | Rising incidence of breast cancer: relationship to stage and receptor status. | J Natl Cancer Inst | 1990 | https://conductscience.org/library/papers/2319611 | PubMed |
| 7 | 25759020 | Smoothened variants explain the majority of drug resistance in basal cell carcinoma. | Cancer Cell | 2015 | https://conductscience.org/library/papers/25759020 | PubMed |
| 8 | 27197169 | The Small Molecule IMR-1 Inhibits the Notch Transcriptional Activation Complex to Suppress Tumorigenesis. | Cancer Res | 2016 | https://conductscience.org/library/papers/27197169 | PubMed |
| 9 | 20624968 | Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. | Proc Natl Acad Sci U S A | 2010 | https://conductscience.org/library/papers/20624968 | PubMed |
| 10 | 23908178 | Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. | Ann Oncol | 2013 | https://conductscience.org/library/papers/23908178 | PubMed |
| 11 | 21876693 | Targeting the tumor microenvironment: focus on angiogenesis. | J Oncol | 2012 | https://conductscience.org/library/papers/21876693 | PubMed |
| 12 | 28073840 | FDA Approval Summary: Sonidegib for Locally Advanced Basal Cell Carcinoma. | Clin Cancer Res | 2017 | https://conductscience.org/library/papers/28073840 | PubMed |
| 13 | 28888902 | A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee. | Osteoarthritis Cartilage | 2018 | https://conductscience.org/library/papers/28888902 | PubMed |
| 14 | 16530045 | Crystal structure of the CSL-Notch-Mastermind ternary complex bound to DNA. | Cell | 2006 | https://conductscience.org/library/papers/16530045 | PubMed |
| 15 | 16862189 | Drug penetration in solid tumours. | Nat Rev Cancer | 2006 | https://conductscience.org/library/papers/16862189 | PubMed |
| 16 | 10742152 | Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. | Nat Med | 2000 | https://conductscience.org/library/papers/10742152 | PubMed |
| 17 | 11895119 | Chemistry and chemical biology of taxane anticancer agents. | Chem Rec | 2001 | https://conductscience.org/library/papers/11895119 | PubMed |
| 18 | 23509322 | Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/23509322 | PubMed |
| 19 | 35328602 | Drug Metabolism for the Identification of Clinical Biomarkers in Breast Cancer. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35328602 | PubMed |
| 20 | 22019144 | Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. | Lancet | 2011 | https://conductscience.org/library/papers/22019144 | PubMed |
Cited by48
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 69 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42802225 | Hereditary breast cancer: emerging roles of non-coding RNAs. | Hereditas | 2026 | https://conductscience.org/library/papers/42802225 | PubMed |
| 42701436 | Enhanced anticancer efficacy of Pa-MAP 1.9 peptide-coated silver nanostars on breast cancer cells. | Mater Today Bio | 2026 | https://conductscience.org/library/papers/42701436 | PubMed |
| 42489715 | Liposomes-enabled gemcitabine therapy for breast cancer: in vitro and in vivo studies. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | https://conductscience.org/library/papers/42489715 | PubMed |
| 42405118 | Advances in the design and discovery of small-molecule tyrosine kinase inhibitors for breast cancer. | RSC Adv | 2026 | https://conductscience.org/library/papers/42405118 | PubMed |
| 42370136 | L-arginine metabolism in breast cancer: mechanisms and therapeutic targets. | Front Oncol | 2026 | https://conductscience.org/library/papers/42370136 | PubMed |
| 42218186 | Novel pyridine-based chalcone analogs and triple negative breast cancer: potential therapy & molecular pathways. | Sci Rep | 2026 | https://conductscience.org/library/papers/42218186 | PubMed |
| 42180128 | Breast cancer chemotherapy in transition: predictive markers, resistance mechanisms, and new treatment approaches. | Front Oncol | 2026 | https://conductscience.org/library/papers/42180128 | PubMed |
| 42032115 | An in vitro hydrogel-based model to study dormancy associated drug resistance in metastatic breast cancer spheroids. | NPJ Biomed Innov | 2025 | https://conductscience.org/library/papers/42032115 | PubMed |
| 41971420 | Breast cancer pathogenesis, diagnosis and treatment: a comprehensive review. | Front Oncol | 2026 | https://conductscience.org/library/papers/41971420 | PubMed |
| 41888569 | A novel combination therapy for ER+ breast cancer suppresses drug resistance via an evolutionary double-bind. | Mol Syst Biol | 2026 | https://conductscience.org/library/papers/41888569 | PubMed |
| 41828663 | Design and Multi-Level Biological Evaluation of Naphthyridine-Based Derivatives as Topoisomerase I/II-Targeted Anticancer Agents with Anti-Fowlpox Virus Activity Supported by In Silico Analysis. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41828663 | PubMed |
| 41516029 | Potential Anticancer Effect of Cannabis sativa L. Dichloromethane Extract Through Oxidative Stress-Related Pathways and the Inhibition of the Migration and Invasiveness of Human Breast Cancer Cells (MDA-MB-231 and MCF-7). | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41516029 | PubMed |
| 41236673 | Decoding breast cancer: insights into molecular pathways & therapeutic approaches. | Discov Oncol | 2025 | https://conductscience.org/library/papers/41236673 | PubMed |
| 41234888 | Identification of molecular subtypes for breast cancer based on butyrate metabolism-related genes to assess prognosis and immune landscape. | Transl Cancer Res | 2025 | https://conductscience.org/library/papers/41234888 | PubMed |
| 41171336 | Research progress of DUB enzyme in breast cancer. | Clin Exp Med | 2025 | https://conductscience.org/library/papers/41171336 | PubMed |
| 41098828 | Strategies for the drug development of cancer therapeutics. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/41098828 | PubMed |
| 41050699 | HLA-DR expression in cytotoxic T lymphocytes: a key to boost the therapeutic potential of T cell-based strategies for breast cancer. | Front Immunol | 2025 | https://conductscience.org/library/papers/41050699 | PubMed |
| 40745071 | Targeting iron regulatory protein 2 (IRP2) to disrupt iron metabolism enhances radiosensitivity through mitochondrial dysfunction in breast cancer cells. | Cell Death Discov | 2025 | https://conductscience.org/library/papers/40745071 | PubMed |
| 40586858 | Liquid biopsy in breast cancer: clinical implications of ctDNA and CTCs in diagnosis, treatment and monitoring. | Mol Cell Biochem | 2025 | https://conductscience.org/library/papers/40586858 | PubMed |
| 40519297 | PLCH1 overexpression promotes breast cancer progression and predicts poor prognosis through the ERK1/2-EGR1 axis. | Front Oncol | 2025 | https://conductscience.org/library/papers/40519297 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35968356
GET https://conductscience.org/api/papers/v1/35968356/references?page=2